Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

10338	Companies
214639	Keywords
144450	Articles
113683	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 02/01/2024 at 13:00, 2 years 3 months ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
PRESS RELEASE

published on 01/31/2024 at 23:45, 2 years 3 months ago

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
PRESS RELEASE

published on 01/08/2024 at 13:00, 2 years 3 months ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
PRESS RELEASE

published on 12/20/2023 at 22:05, 2 years 4 months ago

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRESS RELEASE

published on 12/15/2023 at 00:00, 2 years 4 months ago

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
PRESS RELEASE

published on 12/14/2023 at 12:30, 2 years 4 months ago

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
PRESS RELEASE

published on 12/12/2023 at 14:00, 2 years 4 months ago

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
PRESS RELEASE

published on 12/07/2023 at 13:00, 2 years 4 months ago

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
PRESS RELEASE

published on 11/14/2023 at 13:00, 2 years 5 months ago

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
PRESS RELEASE

published on 11/08/2023 at 22:15, 2 years 5 months ago

Moderna to Present at Upcoming Conferences in November 2023

Accesswire

Published on 05/04/2026 at 10:30, 18 minutes ago

Storm Exploration Plans Drill Program to Test VMS Target at Gold Standard
Published on 05/04/2026 at 01:40, 9 hours 8 minutes ago

New Head of Corporate Affairs and Sustainability
Published on 05/02/2026 at 21:00, 1 day 13 hours ago

GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 2 days 9 hours ago

Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 2 days 9 hours ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants

View all ACCESSWIRE

EQS Group

Published on 05/04/2026 at 10:00, 47 minutes ago

Original-Research: UmweltBank AG (von GBC AG): BUY
Published on 05/04/2026 at 09:49, 58 minutes ago

EPH Group AG starts trading on XETRA
Published on 05/04/2026 at 09:21, 1 hour 26 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 05/04/2026 at 09:18, 1 hour 29 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 05/04/2026 at 09:05, 1 hour 42 minutes ago

Hach Launches Next-Generation DR4900 Spectrophotometer, Setting a New Industry Standard for Fast, Error-Free Water Analysis

Les Echos

Published on 05/04/2026 at 09:51, 56 minutes ago

GUILLEMOT CORPORATION : Déclaration hebdomadaire des transactions sur actions propres du 27 avril 2026 au 1er mai 2026
Published on 05/04/2026 at 09:51, 56 minutes ago

GUILLEMOT CORPORATION: Weekly report share buyback From April 27th 2026 to May 1st 2026
Published on 05/04/2026 at 08:45, 2 hours 3 minutes ago

Air Liquide divests its biogas production activities in four countries
Published on 05/04/2026 at 08:45, 2 hours 3 minutes ago

Air Liquide cède ses activités de production de biogaz dans quatre pays
Published on 05/04/2026 at 08:30, 2 hours 18 minutes ago

ENGIE concrétise ses deux premiers projets éoliens en mer en France

View all LES ECHOS COMFI WIRE